Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
111 stopped studies mapped to Aggressive Non-Hodgkin Lymphoma and descendants · 84% state a reason
Over the 111 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell… | Phase 2 | terminated | Sep 15, 2011 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT02483000 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating… | Phase 1 | terminated | Jun 26, 2015 | Fred Hutchinson Cancer Center | Closed early due to lack of funding | Funding |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | Phase 1 | withdrawn | Jan 18, 2020 | National Cancer Centre, Singapore | PI has left the institution. | Other (stated, no rule matched) |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT02087878 | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel…(HSTCL) | — | withdrawn | Mar 14, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02776891 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH… | Phase 2 | withdrawn | May 18, 2016 | University of California, San Francisco | Unexpected dose production issues prevented study start up | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for… | Phase 2 | terminated | Oct 30, 2015 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | Phase 2 | terminated | Sep 23, 2013 | Cell Medica Ltd | Insufficient enrollment rate | Enrollment / accrual |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | Phase 1 | terminated | Mar 8, 2016 | Seagen Inc. | not stated | Not stated |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Mar 15, 2013 | Ohio State University Comprehensive Cancer Center | Slow patient enrollment and study discontinued after 14 patients enrolled | Enrollment / accrual |
| NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat… | Phase 3 | terminated | Feb 9, 2015 | Sun Yat-sen University | The study is out of date | Other (stated, no rule matched) |
| NCT02533323 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | Phase 2 | terminated | Aug 26, 2015 | Sun Yat-sen University | not stated | Not stated |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa,…(R²-DHAP) | Phase 1 / Phase 2 | terminated | Dec 6, 2016 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Phase II: no scientific interests are given anymore | Other (stated, no rule matched) |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell… | Phase 1 | terminated | Mar 7, 2016 | UNC Lineberger Comprehensive Cancer Center | Lack of funding | Funding |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T…(Gifox-B) | Phase 2 | terminated | Jun 21, 2016 | National Cancer Centre, Singapore | Slow recruitment | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Feb 7, 2006 | National Cancer Institute (NCI) | NCI stopped supplying fenretinide in November of 2012. | Other (stated, no rule matched) |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell,… | Phase 2 | terminated | Jul 19, 2011 | OHSU Knight Cancer Institute | Study closed by PI due to lower than expected accrual. | Enrollment / accrual |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or… | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced… | N/A | terminated | Aug 10, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 20, 2021source: clinicaltrials